BMS Offers Lifeline to Summit's Seglin Tech in $300M Alliance
By Cormac Sheridan
Tuesday, September 11, 2012
Shares in Summit plc gained 26 percent Tuesday on news of a collaboration agreement on the company's Seglin technology with Bristol-Myers Squibb Co. (BMS) that could be worth as much as $300 million in research, development and regulatory milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.